NSD3 keeps IRF3 active

Mino, Takashi; Takeuchi, Osamu

doi:10.1084/jem.20171980

“…Nuclear receptor binding SET domain protein-3 (NSD3) is a member of the histone lysine methyltransferase family involved and is in the regulation of gene expression, cycle progression, and chromatin remodeling (12,13). Aberrant NSD3 expression is associated with many pathophysiological processes, including cardiac hypertrophy (14) and antiviral immune responses (15). Although accumulating evidence indicates that NSD3 affects tumorigenesis and metastasis by regulating the Wnt, Notch, and other signaling pathways (16-18), the role of NSD3 in tumors has not been fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Immunological Characterization of NSD3 Evaluated through an Integrative Pan-Cancer Analysis

Li

¹

,

Liu

²

,

Yao

³

et al. 2021

Preprint

0

View full text Add to dashboard Cite

Background: Nuclear receptor binding SET domain protein-3 (NSD3) has been reported to be a crucial regulator of carcinogenesis as a histone lysine methyltransferase in multiple cancer types. However, the underlying mechanisms have not been clearly delineated. Therefore, we aimed to investigate the expression pattern, prognostic value, and potential function of NSD3 in 33 types of human cancer. Methods: The potential roles of NSD3 were explored using datasets from The Cancer Genome Atlas (TCGA) pan-cancer dataset and an array of bioinformatics methods, including analyses of the relationship between NSD3 expression and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA amplification, and immune cell inﬁltration across 33 cancer types. Results: Many types of cancers are characterized according to the dysregulation of NSD3, which is associated with the pathological stage of cancer. Patients in our study with higher NDS3 levels, which were attributed to NSD3 copy number amplification, always experienced shorter survival periods. Additionally, NSD3 expression was associated with TMB and MSI in 10 different cancer types. The top five cancers whose NSD3 expression correlated with immune scores were further analyzed. The levels of immune-cell infiltration differed significantly between high and low NSD3-expressing samples in each of the five cancer types. Functional enrichment of the NSD3 co-expressed genes indicated a role for NSD3 in the regulation of immune responses and tumorigenesis. Conclusions: Our study revealed that NSD3 can function as a prognostic marker in various cancers due to its role in tumorigenesis and tumor immunity.

show abstract

“…Nuclear receptor binding SET domain protein-3 (NSD3) is a member of the histone lysine methyltransferase family involved and is in the regulation of gene expression, cycle progression, and chromatin remodeling (12,13). Aberrant NSD3 expression is associated with many pathophysiological processes, including cardiac hypertrophy (14) and antiviral immune responses (15). Although accumulating evidence indicates that NSD3 affects tumorigenesis and metastasis by regulating the Wnt, Notch, and other signaling pathways (16)(17)(18), the role of NSD3 in tumors has not been fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Immunological Characterization of NSD3 Evaluated Through an Integrative Pan-Cancer Analysis

Li

¹

,

Liu

²

,

Yao

³

et al. 2021

Preprint

0

View full text Add to dashboard Cite

Background: Nuclear receptor binding SET domain protein-3 (NSD3) has been reported to be a crucial regulator of carcinogenesis as a histone lysine methyltransferase in multiple cancer types. However, the underlying mechanisms have not been clearly delineated. Therefore, we aimed to investigate the expression pattern, prognostic value, and potential function of NSD3 in 33 types of human cancer. Methods: The potential roles of NSD3 were explored using datasets from The Cancer Genome Atlas (TCGA) pan-cancer dataset and an array of bioinformatics methods, including analyses of the relationship between NSD3 expression and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA amplification, and immune cell inﬁltration across 33 cancer types. Results: Many types of cancers are characterized according to the dysregulation of NSD3, which is associated with the pathological stage of cancer. Patients in our study with higher NDS3 levels, which were attributed to NSD3 copy number amplification, always experienced shorter survival periods. Additionally, NSD3 expression was associated with TMB and MSI in 10 different cancer types. The top five cancers whose NSD3 expression correlated with immune scores were further analyzed. The levels of immune-cell infiltration differed significantly between high and low NSD3-expressing samples in each of the five cancer types. Functional enrichment of the NSD3 co-expressed genes indicated a role for NSD3 in the regulation of immune responses and tumorigenesis. Conclusions: Our study revealed that NSD3 can function as a prognostic marker in various cancers due to its role in tumorigenesis and tumor immunity.

show abstract

WHSC1L1-mediated epigenetic downregulation of VMP1 participates in herpes simplex virus 1 infection-induced mitophagy impairment and neuroinflammation

Yao,

Gu,

Li

et al. 2023

Molecular Immunology

1

0

View full text Add to dashboard Cite

NSD3 keeps IRF3 active

Cited by 5 publications

References 16 publications

Prognostic and Immunological Characterization of NSD3 Evaluated through an Integrative Pan-Cancer Analysis

Prognostic and Immunological Characterization of NSD3 Evaluated through an Integrative Pan-Cancer Analysis

Prognostic and Immunological Characterization of NSD3 Evaluated Through an Integrative Pan-Cancer Analysis

WHSC1L1-mediated epigenetic downregulation of VMP1 participates in herpes simplex virus 1 infection-induced mitophagy impairment and neuroinflammation

Contact Info

Product

Resources

About